SUPN

SEC source: 0001104659-22-093748 · tm2223647-3_4seq1.xml · nonDerivative · entry 2

Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,220

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022.

SEC source: 0001104659-22-093748 · tm2223647-3_4seq1.xml · nonDerivative · entry 1

Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,220

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022.

SEC source: 0001104659-22-092614 · tm2223647-2_4seq1.xml · derivative · entry 6

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,895

Underlying: Common Stock · 39,530 shares

Expires 2023-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F5 · derivative.exercise_date: The stock appreciation right vested in four equal annual installments beginning on February 5, 2014.

SEC source: 0001104659-22-092614 · tm2223647-2_4seq1.xml · nonDerivative · entry 3

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 775,559

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.07, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001104659-22-092614 · tm2223647-2_4seq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 790,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.

F2 · shares: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.07, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001104659-22-092614 · tm2223647-2_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 799,431

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

SEC source: 0001104659-22-092204 · tm2223647-1_4seq1.xml · derivative · entry 6

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,425

Underlying: Common Stock · 46,575 shares

Expires 2023-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F5 · derivative.exercise_date: The stock appreciation right vested in four equal annual installments beginning on February 5, 2014.

SEC source: 0001104659-22-092204 · tm2223647-1_4seq1.xml · nonDerivative · entry 3

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 759,901

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.13, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001104659-22-092204 · tm2223647-1_4seq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 777,203

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.

F2 · shares: Pursuant to the terms of the stock appreciation right ("SAR"), upon settlement of the SAR the Reporting Person is entitled to receive shares of common stock in an amount equal to the excess of the fair market value of the common stock on the date of exercise over the base value per share of common stock established at the time the SAR was granted. This transaction reports the number of shares of common stock equal to the difference between the number of shares underlying the exercised SAR and the number of shares issued to the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.13, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001104659-22-092204 · tm2223647-1_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 788,016

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

SEC source: 0001104659-22-089438 · tm2222645-5_4seq1.xml · derivative · entry 5

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 44,900 shares

Expires 2023-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014.

SEC source: 0001104659-22-089438 · tm2222645-5_4seq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 741,441

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.51, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001104659-22-089438 · tm2222645-5_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 769,878

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

SEC source: 0001104659-22-088700 · tm2222645-4_4seq1.xml · derivative · entry 5

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,900

Underlying: Common Stock · 63,100 shares

Expires 2023-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014.

SEC source: 0001104659-22-088700 · tm2222645-4_4seq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 724,978

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.64, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001104659-22-088700 · tm2222645-4_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 764,409

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

SEC source: 0001104659-22-088044 · tm2222645-3_4seq1.xml · derivative · entry 6

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,000

Underlying: Common Stock · 192,000 shares

Expires 2023-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014.

SEC source: 0001104659-22-088044 · tm2222645-3_4seq1.xml · nonDerivative · entry 3

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 701,309

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.960 to $32.535, inclusive. The reporting person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.

SEC source: 0001104659-22-088044 · tm2222645-3_4seq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 711,341

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.950 to $31.950, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.

SEC source: 0001104659-22-088044 · tm2222645-3_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 819,216

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

F1 · price: Transaction made pursuant to a 10b5-1 trading plan adopted June 12, 2022.

SEC source: 0001104659-22-086723 · tm2222645-2_4seq1.xml · derivative · entry 3

Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2023-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022.

F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 5, 2014.

SEC source: 0001104659-22-086723 · tm2222645-2_4seq1.xml · nonDerivative · entry 2

Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 87,220

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022.

SEC source: 0001104659-22-086723 · tm2222645-2_4seq1.xml · nonDerivative · entry 1

Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,220

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted May 19, 2022.

SEC source: 0001104659-22-086729 · tm2222645-1_4seq1.xml · nonDerivative · entry 1

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,644

F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on April 30, 2021.

SEC source: 0001104659-22-037189 · tm229661-2_4seq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Indirect · By the KBT Trust

Disclosed balance after: 1,047,700

F1 · date: The Reporting Person was first notified of the completed transaction by the transfer agent on the filing date.

F2 · price: The Reporting Person is filing this Form 4 to reflect the fact that 10,750 shares were transferred from the KBT Trust to the Reporting Person on March 18, 2022 without consideration and are now owned directly.

SEC source: 0001104659-22-037189 · tm229661-2_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 627,216

F1 · date: The Reporting Person was first notified of the completed transaction by the transfer agent on the filing date.

F2 · price: The Reporting Person is filing this Form 4 to reflect the fact that 10,750 shares were transferred from the KBT Trust to the Reporting Person on March 18, 2022 without consideration and are now owned directly.

SEC source: 0001104659-22-035103 · tm229661-1_4seq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 616,466

F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021.

SEC source: 0001104659-23-003861 · tm233200-2_4aseq1.xml · derivative · entry 5

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2031-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: On February 19, 2021, the Reporting Person was awarded Performance Shares Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.

SEC source: 0001104659-23-003861 · tm233200-2_4aseq1.xml · nonDerivative · entry 2

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 576,466

F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021.

SEC source: 0001104659-23-003861 · tm233200-2_4aseq1.xml · nonDerivative · entry 1

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 556,466

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 19, 2021.

SEC source: 0001104659-22-026875 · tm227622-2_4seq1.xml · derivative · entry 3

NEWHALL CHARLES W III · CIK 0001005544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,882

Underlying: Common Stock · 3,882 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026875 · tm227622-2_4seq1.xml · derivative · entry 2

NEWHALL CHARLES W III · CIK 0001005544 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,847

Underlying: Common Stock · 6,847 shares

Expires 2032-02-22

SEC source: 0001104659-22-026877 · tm227622-10_4seq1.xml · derivative · entry 2

Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026877 · tm227622-10_4seq1.xml · derivative · entry 1

Rubin Jonathan · CIK 0001836067 · SVP, Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023.

SEC source: 0001104659-22-026881 · tm227622-9_4seq1.xml · derivative · entry 3

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026881 · tm227622-9_4seq1.xml · derivative · entry 2

Mottola Frank · CIK 0001804567 · SVP, Quality, GMP, Ops, IT

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-02-22

F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023.

SEC source: 0001104659-22-026876 · tm227622-3_4seq1.xml · derivative · entry 3

Hudson Frederick M. · CIK 0001438462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,882

Underlying: Common Stock · 3,882 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026876 · tm227622-3_4seq1.xml · derivative · entry 2

Hudson Frederick M. · CIK 0001438462 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,847

Underlying: Common Stock · 6,847 shares

Expires 2032-02-22

SEC source: 0001104659-22-026880 · tm227622-6_4seq1.xml · derivative · entry 3

SIEBERT JOHN M · CIK 0001190558 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,882

Underlying: Common Stock · 3,882 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026880 · tm227622-6_4seq1.xml · derivative · entry 2

SIEBERT JOHN M · CIK 0001190558 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,847

Underlying: Common Stock · 6,847 shares

Expires 2032-02-22

SEC source: 0001104659-22-026879 · tm227622-5_4seq1.xml · derivative · entry 2

DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,000

Underlying: Common Stock · 2,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026879 · tm227622-5_4seq1.xml · derivative · entry 1

DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-02-22

F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023.

SEC source: 0001104659-22-026874 · tm227622-1_4seq1.xml · derivative · entry 3

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,882

Underlying: Common Stock · 3,882 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026874 · tm227622-1_4seq1.xml · derivative · entry 2

GEMAYEL GEORGES · CIK 0001256088 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,847

Underlying: Common Stock · 6,847 shares

Expires 2032-02-22

SEC source: 0001104659-22-026884 · tm227622-7_4seq1.xml · derivative · entry 4

Khattar Jack A. · CIK 0001539937 · Director · President, CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2032-02-22

F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023.

SEC source: 0001104659-22-026883 · tm227622-8_4seq1.xml · derivative · entry 3

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026883 · tm227622-8_4seq1.xml · derivative · entry 2

Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2032-02-22

F2 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023.

SEC source: 0001104659-22-026878 · tm227622-4_4seq1.xml · derivative · entry 3

Barlow Carrolee · CIK 0001745316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,882

Underlying: Common Stock · 3,882 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F2 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F2 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

SEC source: 0001104659-22-026878 · tm227622-4_4seq1.xml · derivative · entry 2

Barlow Carrolee · CIK 0001745316 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,847

Underlying: Common Stock · 6,847 shares

Expires 2032-02-22

SEC source: 0001104659-22-026873 · tm227622-11_4seq1.xml · derivative · entry 3

Martin Tami Tillotson · CIK 0001539494 · Sr. V.P., Regulatory Affairs

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.

F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023.